is a six items score, at hospital admission, that showed to be potentially useful for clinical practice 3 . Totaled Health Risks in Vascular Events (THRIVE) score (totaled health risks in vascular events) is calculated with age, NIHSS, and the presence of hypertension, diabetes mellitus, and atrial fibrillation and was validated to predicting clinical outcome and hemorrhagic transformation in patients receiving tPA and showed to be a simple score to help clinicians to estimate outcome and death after acute IS 4 . These four scores were not yet compared and their reproducibility has been tested only in Europe, North America, and Asia.
Stroke is the leading cause of death and disability in Brazil
5
. IS accounts for more than 80% of all stroke types in Brazil 6 . In recent years, a growing number of stroke centers have been settled in this country 7 . Consequently, an increasing number of patients with acute IS have benefited from validated therapies, including the use of tPA 8 . However, only few studies have evaluated IS outcome in Brazil 9 and none of them have assessed the utility of prognostic scores in a Brazilian population. The aim of the present study was to compare the performance of NIHSS, SP-100, ASTRAL, and THRIVE scores to predict in-hospital mortality and functional outcome in an acute IS Brazilian population.
METHOD
Charts of patients assisted at Hospital Paulistano, a Joint Commission International certified stroke center located in the central region of São Paulo, between 2012 and 2014, were reviewed. This study protocol was approved by the Ethics Committee on Research of Hospital Paulistano (Amil Stroke Network).
Patients and procedures
We retrospectively evaluated the clinical records of all patients admitted with suspected or confirmed stroke. The diagnoses were made by neurologists with expertise in cerebrovascular disease through clinical and radiological evaluation. All patients underwent at least one computed tomography scan of the brain (CT scan) to confirm the diagnosis. Only patients diagnosed as having IS were included in the analysis.
Age, gender, stroke risk factors (hypertension, smoking, familial history of vascular diseases, diabetes, previous stroke or transient ischemic attack) were compiled. Data on clinical presentation, NIHSS, capillary glucose level, and vital signs on admission were also recorded.
Prognostic scores
The prognostic scales as well as their cut-offs were used as described in previous studies. According to NIHSS patients were allocated into three subgroups (0 to 5, 6 to 15, and ≥ 16)
1
. SPAN-100 was calculated by the sum of the age in years and the NIHSS. The adopted cut off for SPAN-100 was 100 and patients were divided into two groups, one with SPAN-100 < 100 and other with SPAN-100 ≥ 100 2 . ASTRAL score was calculated by the sum of age (1 point for every 5 years), NIHSS, time delay from onset to admission (0 points when onset to admission was < 3 hours, 2 points when it was more than 3 hours), range of visual deficit (0 points in the absence of visual field defect, 2 points for any stroke-related visual field defect), acute glucose < 3.7 mmol/L or > 7.3 mmol/L (1 point), and decreased level of consciousness (3 points). An ASTRAL score ≥ 31 was adopted as an indicator of unfavourable outcome 3 . THRIVE score was calculated by the sum of age (1 point for age of 60 to 79 years, 2 points for an age ≥ 80 years), 2 points for a NIHSS of 11 to 20, 4 points for a NIH ≥ 21, and 1 point for each hypertension, diabetes mellitus, and fibrillation. The THRIVE ranged from 0 to 9 and the patients were divided in three subgroups (0 to 2, 3 to 5, and 6 to 9)
Data analysis
Statistical analysis was performed using SPSS version 15.0 for Windows. The confidence interval was of 95% and the significance level was set at p < 0.05. Normality was assessed using the Kolmogorov-Smirnov test. In-hospital mortality and modified Rankin score (mRs) at discharge, whereby the patients were divided in two groups, one with mRS ≤ 2 and other with mRs > 2, were defined as outcomes measures. Univariate analysis was carried out with Mann-Whitney test for continuous variables and chi-square for categorical variables. A binary logistic regression analysis was performed with mRS and in-hospital mortality as dependent variables. A sensitivity analysis was conducted to compare the three scores. Area under the receiver operator curves (AUROC) and 95% CIs were calculated as a measure of predictive ability. According to the AUROC result the predictive ability was considered excellent (0.9 to 0.99), good (0.8 to 0.89), fair (0.7 to 0.79), poor (0.6 to 0.69), and failure (0.5 to 0.59).
RESULTS
Three hundred fifty one patients were admitted with stroke or suspected stroke in the period of the study. Among them, two hundred six patients (58.7%) had the diagnosis of IS and were included in the analysis. The mean ± standard deviation (SD) age was 67.58 ± 15.5 years and 55.3% of patients were male. Table 1 shows the comparisons of the characteristics of patients who had favorable functional outcome (mRs ≥ 2) with those of patients with poor functional outcome (mRs > 2). By univariate analysis, patients with mRs > 2 had higher age (p = 0.002), higher percentage of NIHSS ≥ 16 at admission (p < 0.001), higher percentage of SPAN-100 ≥ 100 (p < 0.001), higher percentage of ASTRAL ≥ 31 (p < 0.001), and higher percentages of THRIVE 3 to 5 and THRIVE > 5 (p < 0.001). After adjusted analysis, none of these variables were independently associated with mRs > 2. Table 2 shows the comparisons of baseline characteristics of survivors and patients who died during hospitalization. No significant differences were found between these two groups.
NIHSS subgroups were fairly predictive of mRs > 2 (AUROC 0.754; 0.644 to 0.810, p < 0.001) and were not predictive of in-hospital mortality (AUROC 0.546; 0.409 to 0.683, p = 0.495). SPAN-100 ≥ 100 was poorly predictive of poor functional outcome (AUROC 0.591; 0.5 to 0.683, p = 0.041) and was not predictive of in-hospital mortality (AUROC 0.520; 0.386 to 0.654, p = 0.766). ASTRAL ≥ 31 was poorly predictive of mRs > 2 (AUROC 0.668; 0.577 to 0.758, p < 0.001) and not predictive of in-hospital mortality (AUROC 0.556; 0.428 to 0.705, p = 0.321). THRIVE subgroups were fairly predictive of mRs > 2 (AUROC 0.720; 0.641 to 0.800, p < 0.001) and were poorly predictive of in-hospital mortality (AUROC 0.636; 0.513 to 0.758, p = 0.042) (Figure) .
DISCUSSION
In the present study none of the scores demonstrated good or excellent ability to predict in-hospital mortality and functional outcome in the studied population. THRIVE score was the only score to predict death but the accuracy was poor. THRIVE and NIHSS were fairly accurate to predict worse functional outcome at hospital discharge. In previous studies THRIVE was shown to be a good predictor of clinical outcome, hemorrhagic transformation, and outcome after endovascular 10 and intravenous stroke treatment 11, 12 . This score has been previously tested in North American, European, and Asian populations; however, to the best of our knowledge, this was the first study to evaluate this score in a South American population. The THRIVE score can be easily calculated and can be quickly performed with data routinely obtained during the initial clinical evaluation, such as age, NIHSS, and risk factors (hypertension, diabetes, and atrial fibrillation), without the need of neuroimaging and laboratory testing 4 . Despite the fact THRIVE was the score with better performance, it had not an AUROC above the threshold of 0.8, which is required for clinical use. These results should be interpreted cautiously since our study was small and was carried out in a single institution. Future studies are needed to better assess and validate the use of THRIVE in the Brazilian population.
SPAN-100 did not predict well in-hospital mortality and functional outcome. This finding is in line with a previous study also demonstrating poor performance of SPAN-100 to predict outcomes at 3 and 12 months in Chinese population 12 . ASTRAL score was previously shown to be a reliable predictor of 5-year functional outcome and mortality 13 and a good predictor of unfavorable outcome at 3 and 12 months in Chinese population 14, 15 . In the present study ASTRAL poorly predicted functional outcome and did not predict in-hospital mortality. The difference between our findings and the previous studies evaluating ASTRAL performance must be viewed with caution. In the present study we evaluated in-hospital outcomes, ie, functional status at discharge and in-hospital mortality, while the previous studies evaluated prognosis at 3 months or more. It is possible that these differences explain why none of the tested variables were independently associated with functional outcome and in-hospital mortality.
Our study has limitations that deserve comment. First, the number of included patients was small. Consequently, these results need confirmation in larger stroke registries or in prospective studies. Also, we did not follow the patients after discharge, so there are not data concerning 3-and 12-month outcomes. As strengthens of the study it must be mentioned the homogeneity of the sample, since all the patients were from a single institution and the same stroke team evaluated all patients.
The use of prognostic scores may help clinicians, since the clinical evaluation alone is inaccurate 16 . To contribute to clinicians, the score must be highly effective in prognostic evaluation and easily applied during the first clinical evaluation. The use of such scales, in this context, can help better target the use of therapeutic resources, especially in countries where limited resources to treat stroke patients are available, such as the low to medium income countries. The present results do not allow, to date, the recommendation of these scores for clinical use in Brazilian population. Future and larger studies are still necessary to reassess the accuracy of these scales, specially THRIVE which showed to be the most promising of the four evaluated scales. 
